Progress in head and neck cancer immunotherapy: can tolerance and immune suppression be reversed? (Q36019207)

11 August 2017

1 reference

title

Progress in head and neck cancer immunotherapy: can tolerance and immune suppression be reversed? (English)

1 reference

11 August 2017

1 reference

1 reference

1 reference

head and neck carcinoma

1 reference

1

Robert L Ferris

1 reference

PubMed ID

15668533

11 August 2017

language of work or name

1 reference

1 January 2004

1 reference

11 August 2017

1 reference

11 August 2017

66

1 reference

11 August 2017

332-340

1 reference

11 August 2017

6

1 reference

Innate direct anticancer effector function of human immature dendritic cells. I. Involvement of an apoptosis-inducing pathway

11 August 2017

1 reference

Role of TNF family ligands in antitumor activity of natural killer cells

21 January 2018

1 reference

Identification and design of p53-derived HLA-A2-binding peptides with increased CTL immunogenicity.

21 January 2018

1 reference

Therapy of murine tumors with p53 wild-type and mutant sequence peptide-based vaccines

21 January 2018

1 reference

Cancer therapy with DNA-based vaccines

21 January 2018

1 reference

Human tumor-derived genomic DNA transduced into a recipient cell induces tumor-specific immune responses ex vivo.

21 January 2018

1 reference

Comparison of HPV DNA vaccines employing intracellular targeting strategies

21 January 2018

1 reference

Regression of HPV-positive tumors treated with a new Listeria monocytogenes vaccine.

21 January 2018

1 reference

Gene therapy for head and neck cancer

21 January 2018

1 reference

Alloantigen gene therapy for head and neck cancer: evaluation of animal models

21 January 2018

1 reference

Combination nonviral cytokine gene therapy for head and neck cancer

21 January 2018

1 reference

A phase I vaccine safety and chemotherapy dose-finding trial of an allogeneic GM-CSF-secreting breast cancer vaccine given in a specifically timed sequence with immunomodulatory doses of cyclophosphamide and doxorubicin

21 January 2018

1 reference

Cytokine modified tumor vaccines

21 January 2018

1 reference

Gene therapy--phase I trial for primary untreated head and neck squamous cell cancer (HNSCC) UICC stage II-IV with a single intratumoral injection of hIL-2 plasmids formulated in DOTMA/Chol

21 January 2018

1 reference

Covalent linking of proteins and cytokines to suture: Enhancing the immune response of head and neck cancer patients

21 January 2018

1 reference

Identification of NY-ESO-1, MAGE-1, and MAGE-3 in head and neck squamous cell carcinoma

21 January 2018

1 reference

A CASP-8 mutation recognized by cytolytic T lymphocytes on a human head and neck carcinoma.

21 January 2018

1 reference

The Ability of Variant Peptides to Reverse the Nonresponsiveness of T Lymphocytes to the Wild-Type Sequence p53264-272 Epitope

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1159/000081891

1 reference

11 August 2017

1 reference

PubMed ID

15668533